Virpax Pharmaceuticals, Inc.
VRPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.21 | -0.11 | -5.77 |
| FCF Yield | -41,351.34% | -10.52% | -9.80% | -1.45% |
| EV / EBITDA | -0.00 | -5.57 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 1,322.00% | -811.13% | -130.58% | -32.33% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1,384.98 | 0.65 | 0.82 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -169,509.16% | 44.79% | -22.72% | -950.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.60 | 0.00 | 0.00 |
| Interest Coverage | 116.43 | 0.00 | 0.00 | -129.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |